-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師的觀點摘要如下： Dana Incorporated (DAN)公佈的第一季調整後EBITDA為1.71億美元，高於先前預期的9,300萬美元（成長84%），也高於市場普遍預期的1.6億美元。營收成長5%至18.7億美元（較市場預期高出4,000萬美元），調整後EBITDA利潤率提升400個基點至9.2%（比市場預期高出40個基點）。 DAN第一季調整後EBITDA利潤率的提升主要得益於成本節約和效率提升。管理層表示，該公司在第一季實現了3,500萬美元的額外成本節約。 DAN重申了先前發布的2026年業績指引，管理層表示，Dana 2030計劃清晰地規劃了實現更高銷售額、更高利潤率和更多調整後自由現金流的路徑。 DAN公司表示，第一季回購了440萬股股票，耗資1.25億美元。該公司目前還支付每股0.48美元的年度股息。消息公佈後，DAN的股價幾乎沒有變動。 2025年，DAN的表現遠超其他汽車零件供應商（漲幅達110%，而標普500指數同期漲幅僅為16%），我們認為管理層在利潤率方面取得的顯著進展以及積極的股票回購計劃都是利好因素。
Related Articles
Australia
Mizuho Securities Raises Price Target on Apellis Pharmaceuticals to $41 From $20, Maintains Neutral Rating
Apellis Pharmaceuticals (APLS) has an average rating of hold and mean price target of $40.82, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $40.95, Change: $-0.05, Percent Change: -0.11%
$APLS
Research
Mizuho Securities Downgrades Terns Pharmaceuticals to Neutral From Outperform, Trims Price Target to $53 From $54
Terns Pharmaceuticals (TERN) has an average rating of hold and mean price target of $53, according to analysts polled by FactSet.
$TERN
Research
Research Alert: CFRA Reiterates Buy Opinion On Shares Of Booking Holdings Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month target price by $8 to $196, 19x our 2026 EPS estimate (unchanged) and a discount to its 23x five-year average forward multiple, reflecting geopolitical risks. We lower our 2026 EPS to $10.33 from $10.74 and 2027's to $11.58 from $12.07, primarily reflecting lower gross bookings growth from the Middle East conflict. We maintain our Buy opinion as shares are undervalued given long-term competitive strengths and temporary geopolitical headwinds. The company's Connected Trip platform and Genius loyalty program are supporting higher-margin direct bookings, suggesting AI initiatives are strengthening consumer engagement rather than disintermediating the platform. Strong free cash flow supports future shareholder returns, including $3.6 billion in Q1 buybacks. While the Middle East conflict will impact Q2 bookings, BKNG has a history of seeing travel rebound following geopolitical or economic disruptions. U.S. room night growth accelerated in Q1 to a low-teens range, providing near-term momentum.
$BKNG